Madrigal Pharmaceuticals

NSQ:MDGL · US5588681057

BiotechnologyMedium

360

Value49

Profit price88

Cash yield1

Sales & asset price44

Price/Sales68

EV / Gross Profit61

Price/Book3

Quality48

Returns on capital26

Return on Capital34

Cash Return on Capital19

Return on Equity26

Profit margins65

EBIT Margin31

Gross Profitability98

Cash backing56

Accruals67

Owner Earnings Margin45

Growth60

Sales growth67

Profit growth65

Profit Growth69

Long-Term EPS Growth60

Reinvestment87

Price momentum70

Safety49

Debt load19

Debt serviceability43

Refinancing85

Debt Payback1

Liquidity61

Sentiment61

Analyst ratings30

Expectations trend34

Opinion Changes7

Price Target Upside60

Market mood79

Value Creation6/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Madrigal Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeMedium

TypePublic Company

ExchangeNASDAQGS

Employees917

Websitemadrigalpharma.com

ISINUS5588681057

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

HepatologyBiotechnologyMedical DevicePharmaceutical

Description

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (‘MASH’), a serious liver disease with high unmet medical need that can lead to cirrhosis, live…

Analysis

Middle-of-the-road

Madrigal Pharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

100

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Madrigal Pharmaceuticals with its peers

Sagimet Biosciences

NMQ:SGMT

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Galectin Therapeutics

NAQ:GALT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

MediciNova

NMQ:MNOV

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Seres Therapeutics

NSQ:MCRB

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Aurinia Pharmaceuticals

NMQ:AUPH

CountryCanada

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tectonic Therapeutic

NMQ:TECX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →